Basic Information
Nexavar
Regulatory Information
EMEA/H/C/000690
July 19, 2006
35
June 7, 2024
Company Information
Germany
Kaiser-Wilhelm-Allee 1 51373 Leverkusen
BAYER AG
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication **Hepatocellular carcinoma** Nexavar is indicated for the treatment of hepatocellular carcinoma. **Renal cell carcinoma** Nexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy. **Differentiated thyroid carcinoma** Nexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Nexavar. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Nexavar.